Gabelli & Co Investment Advisers’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-34,300	Closed	-$344K	–	291
2023 Q4	$344K	Buy	+34,300	New	+$156K	0.06%	138

Gabelli & Co Investment Advisers's GRCL Position: Q1 2024 in Review

Gabelli & Co Investment Advisers sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 34,300 shares — an estimated $344K sold.

Gabelli & Co Investment Advisers first reported a position in GRCL in Q4 2023 and held it in 1 quarter. The position peaked at $344K in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Gabelli & Co Investment Advisers reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 34,300 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $344K.
Gabelli & Co Investment Advisers first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2023 and held it in 1 quarter.
Gabelli & Co Investment Advisers's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $344K in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2024, filed 14 May 2024.